Europe Contraceptives Market size surpassed USD 5.1 billion in 2021 and is anticipated to expand at 6.8% CAGR from 2022 to 2028.
Contraceptives refer to the drug or devices that are used to prevent pregnancy, reduce risks of sexually transmitted diseases, etc. Contraceptives are used to interfere with the normal process of sperm-ovum fertilization to avoid unintended pregnancy. These drugs or devices are considered as a safe, simple, and convenient way to prevent pregnancy. They are widely utilized in protection from bacterial and viral infections.
Get more details on this report - Request Free Sample PDF
Increasing prevalence of sexually transmitted diseases (STD) in European countries is set to positively impact the market growth. As per the latest research statistics, contraception comprising pills, patches, rings, etc. are highly effective in preventing STDs. For example, according to the Public Institute’s latest data, over 90,000 people are suffering from human immunodeficiency virus infection (HIV) in Germany.
Growing inclination and implementation of favorable initiatives by the government to promote awareness concerning unintended pregnancies and family planning are some of the key variables driving the Europe contraceptives market size. Sexual and reproductive health and rights (SRHR) organization is actively working to provide a variety of sexual & reproductive health counseling and services through over 150 clinics in Germany. In European countries, several programs are operating to upsurge awareness among the young population pertaining to sexual & reproductive health. Such initiatives have further increased access to services and knowledge related to the effective prevention of unintended pregnancy.
The contraceptive devices segment accounted for USD 3,603 million revenue in 2021, owing to the rising awareness related to the use of contraceptive devices, easy access to a variety of devices as per consumer requirements, and increasing initiatives to reduce the spread of sexually transmitted diseases (STDs), etc. Companies are emphasizing the researching and developing novel contraceptive devices such as condoms, intra-uterine devices, and diaphragms among others to meet the surging consumer demand. Female condoms are also getting popular in the developed nation comprising the UK and Germany as they aid in reducing the risk of unintended pregnancy and STIs.
UK contraceptives market will reach USD 1,249 million revenue by 2028, due to the surging government spending on improving sexual & reproductive health in the country, presence of established manufacturers, the rising prevalence of sexually transmitted infection, supportive government initiatives, etc.
Furthermore, lesser prices have increased the usage of contraceptive drugs & devices in the country. This demand has surged over the years and is anticipated to rise in the coming years with more awareness & knowledge regarding the benefits of contraceptives. The considerable number of unwanted pregnancies has become one of the serious concerns in the country.
Prominent participants operating across the Europe contraceptives market include Allergan Plc, Bayer Corporation, Cooper Surgical, Inc., Church & Dwight Co., Inc., Mayer Laboratories, Inc., Merck & Co. Inc., Pfizer, Reckitt Benckiser Group Plc and Teva Pharmaceuticals Industries Ltd.
These companies are engaged in several strategic initiatives such as mergers & acquisitions, product launch, distribution agreements to maintain their market position. For instance, in January 2021, Teva Pharmaceuticals Industries Ltd. announced the launch of a generic version of NuvaRing, intended for use by women to prevent unwanted pregnancy. This launch will support the company to expand its contraceptives business portfolio and offer greater flexibility to its customers.